Selected research
Industry Research
Recombinant Human Chorionic Gonadotropin Industry Research Report 2026
Market perspective
The global Recombinant Human Chorionic Gonadotropin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Recombinant Human Chorionic Gonadotropin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Recombinant Human Chorionic Gonadotropin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Recombinant Human Chorionic Gonadotropin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Recombinant Human Chorionic Gonadotropin include Merck, Ferring Pharmaceuticals, Wellona Pharma, Serum International Ltd, Schering Plough, Marvel Oceanic Private Limited, Facmed Pharmaceuticals and Bionomics Lifesciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Recombinant Human Chorionic Gonadotropin market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Recombinant Human Chorionic Gonadotropin Market by Company
Merck
Ferring Pharmaceuticals
Wellona Pharma
Serum International Ltd
Schering Plough
Marvel Oceanic Private Limited
Facmed Pharmaceuticals
Bionomics Lifesciences
Recombinant Human Chorionic Gonadotropin Segment by Type
Intramuscular Powder for Injection
Subcutaneous Solution for Injection
Recombinant Human Chorionic Gonadotropin Segment by Application
Female
Male
Recombinant Human Chorionic Gonadotropin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Human Chorionic Gonadotropin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Human Chorionic Gonadotropin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Human Chorionic Gonadotropin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Recombinant Human Chorionic Gonadotropin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Recombinant Human Chorionic Gonadotropin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Recombinant Human Chorionic Gonadotropin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Intramuscular Powder for Injection
- Subcutaneous Solution for Injection
Applications
- Female
- Male
Companies covered
- Merck
- Ferring Pharmaceuticals
- Wellona Pharma
- Serum International Ltd
- Schering Plough
- Marvel Oceanic Private Limited
- Facmed Pharmaceuticals
- Bionomics Lifesciences
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Recombinant Human Chorionic Gonadotropin Market Size (2021-2032)
- 2.2.2 Global Recombinant Human Chorionic Gonadotropin Sales (2021-2032)
- 2.2.3 Global Recombinant Human Chorionic Gonadotropin Market Average Price (2021-2032)
- 2.3 Recombinant Human Chorionic Gonadotropin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Intramuscular Powder for Injection
- 2.3.3 Subcutaneous Solution for Injection
- 2.4 Recombinant Human Chorionic Gonadotropin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Female
- 2.4.3 Male
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Recombinant Human Chorionic Gonadotropin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Recombinant Human Chorionic Gonadotropin Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Recombinant Human Chorionic Gonadotropin Revenue of Manufacturers (2021-2026)
- 3.4 Global Recombinant Human Chorionic Gonadotropin Average Price by Manufacturers (2021-2026)
- 3.5 Global Recombinant Human Chorionic Gonadotropin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Recombinant Human Chorionic Gonadotropin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Recombinant Human Chorionic Gonadotropin, Product Type & Application
- 3.8 Global Manufacturers of Recombinant Human Chorionic Gonadotropin, Established Date
- 3.9 Global Recombinant Human Chorionic Gonadotropin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck
- 4.1.1 Merck Company Information
- 4.1.2 Merck Business Overview
- 4.1.3 Merck Recombinant Human Chorionic Gonadotropin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck Recombinant Human Chorionic Gonadotropin Product Portfolio
- 4.1.5 Merck Recent Developments
- 4.2 Ferring Pharmaceuticals
- 4.2.1 Ferring Pharmaceuticals Company Information
- 4.2.2 Ferring Pharmaceuticals Business Overview
- 4.2.3 Ferring Pharmaceuticals Recombinant Human Chorionic Gonadotropin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Ferring Pharmaceuticals Recombinant Human Chorionic Gonadotropin Product Portfolio
- 4.2.5 Ferring Pharmaceuticals Recent Developments
- 4.3 Wellona Pharma
- 4.3.1 Wellona Pharma Company Information
- 4.3.2 Wellona Pharma Business Overview
- 4.3.3 Wellona Pharma Recombinant Human Chorionic Gonadotropin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Wellona Pharma Recombinant Human Chorionic Gonadotropin Product Portfolio
- 4.3.5 Wellona Pharma Recent Developments
- 4.4 Serum International Ltd
- 4.4.1 Serum International Ltd Company Information
- 4.4.2 Serum International Ltd Business Overview
- 4.4.3 Serum International Ltd Recombinant Human Chorionic Gonadotropin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Serum International Ltd Recombinant Human Chorionic Gonadotropin Product Portfolio
- 4.4.5 Serum International Ltd Recent Developments
- 4.5 Schering Plough
- 4.5.1 Schering Plough Company Information
- 4.5.2 Schering Plough Business Overview
- 4.5.3 Schering Plough Recombinant Human Chorionic Gonadotropin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Schering Plough Recombinant Human Chorionic Gonadotropin Product Portfolio
- 4.5.5 Schering Plough Recent Developments
- 4.6 Marvel Oceanic Private Limited
- 4.6.1 Marvel Oceanic Private Limited Company Information
- 4.6.2 Marvel Oceanic Private Limited Business Overview
- 4.6.3 Marvel Oceanic Private Limited Recombinant Human Chorionic Gonadotropin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Marvel Oceanic Private Limited Recombinant Human Chorionic Gonadotropin Product Portfolio
- 4.6.5 Marvel Oceanic Private Limited Recent Developments
- 4.7 Facmed Pharmaceuticals
- 4.7.1 Facmed Pharmaceuticals Company Information
- 4.7.2 Facmed Pharmaceuticals Business Overview
- 4.7.3 Facmed Pharmaceuticals Recombinant Human Chorionic Gonadotropin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Facmed Pharmaceuticals Recombinant Human Chorionic Gonadotropin Product Portfolio
- 4.7.5 Facmed Pharmaceuticals Recent Developments
- 4.8 Bionomics Lifesciences
- 4.8.1 Bionomics Lifesciences Company Information
- 4.8.2 Bionomics Lifesciences Business Overview
- 4.8.3 Bionomics Lifesciences Recombinant Human Chorionic Gonadotropin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bionomics Lifesciences Recombinant Human Chorionic Gonadotropin Product Portfolio
- 4.8.5 Bionomics Lifesciences Recent Developments
5 Global Recombinant Human Chorionic Gonadotropin Market Scenario by Region
- 5.1 Global Recombinant Human Chorionic Gonadotropin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Recombinant Human Chorionic Gonadotropin Sales by Region: 2021-2032
- 5.2.1 Global Recombinant Human Chorionic Gonadotropin Sales by Region: 2021-2026
- 5.2.2 Global Recombinant Human Chorionic Gonadotropin Sales by Region: 2027-2032
- 5.3 Global Recombinant Human Chorionic Gonadotropin Revenue by Region: 2021-2032
- 5.3.1 Global Recombinant Human Chorionic Gonadotropin Revenue by Region: 2021-2026
- 5.3.2 Global Recombinant Human Chorionic Gonadotropin Revenue by Region: 2027-2032
- 5.4 North America Recombinant Human Chorionic Gonadotropin Market Facts & Figures by Country
- 5.4.1 North America Recombinant Human Chorionic Gonadotropin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Recombinant Human Chorionic Gonadotropin Sales by Country (2021-2032)
- 5.4.3 North America Recombinant Human Chorionic Gonadotropin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Recombinant Human Chorionic Gonadotropin Market Facts & Figures by Country
- 5.5.1 Europe Recombinant Human Chorionic Gonadotropin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Recombinant Human Chorionic Gonadotropin Sales by Country (2021-2032)
- 5.5.3 Europe Recombinant Human Chorionic Gonadotropin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Recombinant Human Chorionic Gonadotropin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Recombinant Human Chorionic Gonadotropin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Recombinant Human Chorionic Gonadotropin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Recombinant Human Chorionic Gonadotropin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Recombinant Human Chorionic Gonadotropin Market Facts & Figures by Country
- 5.7.1 South America Recombinant Human Chorionic Gonadotropin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Recombinant Human Chorionic Gonadotropin Sales by Country (2021-2032)
- 5.7.3 South America Recombinant Human Chorionic Gonadotropin Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Recombinant Human Chorionic Gonadotropin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Recombinant Human Chorionic Gonadotropin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Recombinant Human Chorionic Gonadotropin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Recombinant Human Chorionic Gonadotropin Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Recombinant Human Chorionic Gonadotropin Sales by Type (2021-2032)
- 6.1.1 Global Recombinant Human Chorionic Gonadotropin Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Recombinant Human Chorionic Gonadotropin Sales Market Share by Type (2021-2032)
- 6.2 Global Recombinant Human Chorionic Gonadotropin Revenue by Type (2021-2032)
- 6.2.1 Global Recombinant Human Chorionic Gonadotropin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Recombinant Human Chorionic Gonadotropin Revenue Market Share by Type (2021-2032)
- 6.3 Global Recombinant Human Chorionic Gonadotropin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Recombinant Human Chorionic Gonadotropin Sales by Application (2021-2032)
- 7.1.1 Global Recombinant Human Chorionic Gonadotropin Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Recombinant Human Chorionic Gonadotropin Sales Market Share by Application (2021-2032)
- 7.2 Global Recombinant Human Chorionic Gonadotropin Revenue by Application (2021-2032)
- 7.2.1 Global Recombinant Human Chorionic Gonadotropin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Recombinant Human Chorionic Gonadotropin Revenue Market Share by Application (2021-2032)
- 7.3 Global Recombinant Human Chorionic Gonadotropin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Recombinant Human Chorionic Gonadotropin Value Chain Analysis
- 8.1.1 Recombinant Human Chorionic Gonadotropin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Recombinant Human Chorionic Gonadotropin Production Mode & Process
- 8.2 Recombinant Human Chorionic Gonadotropin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Recombinant Human Chorionic Gonadotropin Distributors
- 8.2.3 Recombinant Human Chorionic Gonadotropin Customers
9 Global Recombinant Human Chorionic Gonadotropin Analyzing Market Dynamics
- 9.1 Recombinant Human Chorionic Gonadotropin Industry Trends
- 9.2 Recombinant Human Chorionic Gonadotropin Industry Drivers
- 9.3 Recombinant Human Chorionic Gonadotropin Industry Opportunities and Challenges
- 9.4 Recombinant Human Chorionic Gonadotropin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst